# The post-translational modification of NuMA in cancer cells is a new target for cancer eradication

**Authors:** Malka Cohen-Armon

PMC · DOI: 10.1038/s41419-025-07868-7 · 2025-07-18

## TL;DR

A new cancer treatment approach targets NuMA modification to selectively kill cancer cells during mitosis.

## Contribution

A novel cell-death mechanism in cancer cells is revealed through the inhibition of NuMA post-translational modification.

## Key findings

- Inhibiting NuMA modification disrupts its protein-binding capacity in cancer cells.
- Structural faults in mitotic spindle poles lead to mitosis arrest and cancer cell death.
- This mechanism selectively targets malignant cells without relying on their mutation status.

## Abstract

Recent findings identify a cell-death mechanism in human cancer cells, based on the inhibition of the post-translational modification of NuMA (nuclear mitotic apparatus protein) in cancer cells, which interferes with its protein-binding capacity. NuMA is an indispensable protein for mitosis in both malignant and healthy cells. However, in this cell-death mechanism, only malignant cells are eradicated, due to structural faults inserted in the mitotic spindle poles, causing mitosis arrest. Cell death is imposed in the cancer cells by mitosis arrest, disregarding their mutations.

## Linked entities

- **Proteins:** NUMA1 (nuclear mitotic apparatus protein 1)
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** NUMA1 (nuclear mitotic apparatus protein 1) [NCBI Gene 4926] {aka NMP-22, NUMA}
- **Diseases:** cancer (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12274338/full.md

---
Source: https://tomesphere.com/paper/PMC12274338